Afluria is an inactivated influenza vaccine indicated for active immunization against influenza caused by virus subtypes A and type B. It is approved for use in patients aged ≥5 years old.
The company anticipates delivering about 16.5 million doses of the 2014–2015 formulation with about 75% of doses in thimerosal-free prefilled syringes. Healthcare providers who have ordered Afluria may be able to start administering vaccinations as early as this month.
Afluria is available as 0.5mL single-dose prefilled syringes in 10-count cartons, and 5mL multi-dose vials in 1-count cartons.
For more information call (844) 275-2461 or visit Afluria.com.